What ENABLE-2 can do for you

ENABLE-2 is building an antibacterial drug discovery platform based on the learnings from ENABLE (IMI Innovative Medicines Initiative) with focus on the early stages of antibiotic discovery and development. ENABLE-2 is filling a gap, ensuring a complete global development pipeline for new antibiotics.

researcher with test tube

ENABLE-2 is supporting the development of direct acting systemic antibacterial compounds (potentiator molecules are also in scope, e.g. β-lactamase inhibitors). Pathogens in scope for ENABLE-2 are E. coli, K. pneumoniae, P. aeruginosa, A.baumannii, S. aureus and E. faecium (ESKAPE pathogens).

ENABLE-2 logoAn initial call, open exclusively to Swedish research groups, including both academics and SMEs, was conducted October 4–31, 2021. In 2022, ENABLE-2 launched with four promising projects.

The goal of ENABLE-2 is to develop Hits up to a level of advancement where they can successfully graduate to later stage initiatives (e.g., CARB-X, GARDP, REPAIR Impact Fund) or to out-licensing.

THIS IS ENABLE-2

Experimental platform with capabilities in chemistry, microbiology, ADME, safety and in vivo efficacy that will work with Hit owners to advance their compounds towards advanced Lead status. ENABLE-2 provides nondilutive experimental support to early stage antibiotic projects.

Expert knowledge hub  The Portfolio Management Committee (PMC) of ENABLE-2 is composed of international/independent experts with broad antibacterial drug discovery and development experience. They will mentor your programme and advise on challenges as well as on how to mitigate liabilities.

Supports Hit owners acquire key missing data for PMC  If your programme does not fully meet the thresholds for entry into the ENABLE-2 Platform there is a possibility of a Material Transfer Agreement (MTA) Route – a kind of pre-ENABLE-2 development package where this data could be generated.

Maintains data confidentiality  ENABLE-2 adheres to a very restrictive communication policy and will only communicate what you agree upon or what is released by yourself.


Apply to join

Download EoI template

CONTACT

Anders Karlén, Coordinator, Professor
Uppsala University (SE)
anders.karlen@ilk.uu.se, +46 (0)70-167 9177 

Last modified: 2022-08-24